Type 2 Diabetes Research
Type 2 diabetes is characterized by insulin resistance and progressive β-cell dysfunction. Incretin-axis agonists are the largest commercial pharmaceutical category of the 2020s in T2D, with semaglutide (Ozempic, Rybelsus), tirzepatide (Mounjaro), and retatrutide (investigational) representing successive generations of receptor pharmacology.
